SANUWAVE Health R&D Spending Growth & History (SNWV)
SANUWAVE Health's r&d spending was $1.4M for fiscal 2025.
View full SANUWAVE Health company overviewSANUWAVE Health annual r&d spending history
| Fiscal year | Period ended | R&D spending | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $1.4M | $680,000 | +101.04% |
| 2024 | 2024-12-31 | $673,000 | $94,000 | +16.23% |
| 2023 | 2023-12-31 | $579,000 | $12,000 | +2.12% |
| 2022 | 2022-12-31 | $567,000 | −$534,000 | −48.50% |
| 2021 | 2021-12-31 | $1.1M | −$145,000 | −11.64% |
| 2020 | 2020-12-31 | $1.2M | $64,108 | +5.42% |
| 2019 | 2019-12-31 | $1.2M | $200,238 | +20.40% |
| 2018 | 2018-12-31 | $981,654 | −$310,877 | −24.05% |
| 2017 | 2017-12-31 | $1.3M | $163,891 | +14.52% |
| 2016 | 2016-12-31 | $1.1M | −$1.0M | −48.06% |
| 2015 | 2015-12-31 | $2.2M | −$827,988 | −27.59% |
| 2014 | 2014-12-31 | $3.0M | $704,145 | +30.66% |
| 2013 | 2013-12-31 | $2.3M | $534,468 | +30.33% |
| 2012 | 2012-12-31 | $1.8M | −$968,865 | −35.48% |
| 2011 | 2011-12-31 | $2.7M | −$1.1M | −29.60% |
| 2010 | 2010-12-31 | $3.9M | — | — |
SANUWAVE Health quarterly r&d spending
| Fiscal quarter | Period ended | R&D spending | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $628,000 | $434,000 | +223.71% |
| Q1 2026 | 2026-03-31 | $660,000 | $452,000 | +217.31% |
| Q4 2025 | 2025-12-31 | $606,000 | $452,000 | +293.51% |
| Q3 2025 | 2025-09-30 | $345,000 | $184,000 | +114.29% |
| Q2 2025 | 2025-06-30 | $194,000 | −$1,000 | −0.51% |
| Q1 2025 | 2025-03-31 | $208,000 | $45,000 | +27.61% |
| Q4 2024 | 2024-12-31 | $154,000 | $10,000 | +6.94% |
| Q3 2024 | 2024-09-30 | $161,000 | −$4,000 | −2.42% |
| Q2 2024 | 2024-06-30 | $195,000 | $56,000 | +40.29% |
| Q1 2024 | 2024-03-31 | $163,000 | $32,000 | +24.43% |
| Q4 2023 | 2023-12-31 | $144,000 | $71,000 | +97.26% |
| Q3 2023 | 2023-09-30 | $165,000 | $8,000 | +5.10% |
| Q2 2023 | 2023-06-30 | $139,000 | −$32,000 | −18.71% |
| Q1 2023 | 2023-03-31 | $131,000 | −$35,000 | −21.08% |
| Q4 2022 | 2022-12-31 | $73,000 | −$105,000 | −58.99% |
| Q3 2022 | 2022-09-30 | $157,000 | −$140,000 | −47.14% |
| Q2 2022 | 2022-06-30 | $171,000 | −$101,000 | −37.13% |
| Q1 2022 | 2022-03-31 | $166,000 | −$188,000 | −53.11% |
| Q4 2021 | 2021-12-31 | $178,000 | −$84,000 | −32.06% |
| Q3 2021 | 2021-09-30 | $297,000 | −$135,000 | −31.25% |
| Q2 2021 | 2021-06-30 | $272,000 | $7,000 | +2.64% |
| Q1 2021 | 2021-03-31 | $354,000 | $67,000 | +23.34% |
| Q4 2020 | 2020-12-31 | $262,000 | −$51,714 | −16.48% |
| Q3 2020 | 2020-09-30 | $432,000 | $132,097 | +44.05% |
| Q2 2020 | 2020-06-30 | $265,000 | −$42,273 | −13.76% |
| Q1 2020 | 2020-03-31 | $287,000 | $25,998 | +9.96% |
| Q4 2019 | 2019-12-31 | $313,714 | — | — |
| Q3 2019 | 2019-09-30 | $299,903 | −$322,249 | −51.80% |
| Q2 2019 | 2019-06-30 | $307,273 | −$21,480 | −6.53% |
| Q1 2019 | 2019-03-31 | $261,002 | $22,525 | +9.45% |
| Q3 2018 | 2018-09-30 | $622,152 | $355,315 | +133.16% |
| Q2 2018 | 2018-06-30 | $328,753 | −$109,156 | −24.93% |
| Q1 2018 | 2018-03-31 | $238,477 | −$21,861 | −8.40% |
| Q4 2017 | 2017-12-31 | $327,447 | $251,402 | +330.60% |
| Q3 2017 | 2017-09-30 | $266,837 | $364 | +0.14% |
| Q2 2017 | 2017-06-30 | $437,909 | −$38,258 | −8.03% |
| Q1 2017 | 2017-03-31 | $260,338 | −$49,617 | −16.01% |
| Q4 2016 | 2016-12-31 | $76,045 | −$436,228 | −85.16% |
| Q3 2016 | 2016-09-30 | $266,473 | −$302,661 | −53.18% |
| Q2 2016 | 2016-06-30 | $476,167 | $19,378 | +4.24% |
| Q1 2016 | 2016-03-31 | $309,955 | −$324,668 | −51.16% |
| Q4 2015 | 2015-12-31 | $512,273 | −$1,733 | −0.34% |
| Q3 2015 | 2015-09-30 | $569,134 | −$139,170 | −19.65% |
| Q2 2015 | 2015-06-30 | $456,789 | −$556,863 | −54.94% |
| Q1 2015 | 2015-03-31 | $634,623 | −$130,222 | −17.03% |
| Q4 2014 | 2014-12-31 | $514,006 | −$37,721 | −6.84% |
| Q3 2014 | 2014-09-30 | $708,304 | −$67,413 | −8.69% |
| Q2 2014 | 2014-06-30 | $1.0M | $389,119 | +62.31% |
| Q1 2014 | 2014-03-31 | $764,845 | $420,160 | +121.90% |
| Q4 2013 | 2013-12-31 | $551,727 | $181,167 | +48.89% |
| Q3 2013 | 2013-09-30 | $775,717 | $335,524 | +76.22% |
| Q2 2013 | 2013-06-30 | $624,533 | $276,889 | +79.65% |
| Q1 2013 | 2013-03-31 | $344,685 | −$259,112 | −42.91% |
| Q4 2012 | 2012-12-31 | $370,560 | −$192,764 | −34.22% |
| Q3 2012 | 2012-09-30 | $440,193 | −$183,125 | −29.38% |
| Q2 2012 | 2012-06-30 | $347,644 | −$447,474 | −56.28% |
| Q1 2012 | 2012-03-31 | $603,797 | −$145,502 | −19.42% |
| Q4 2011 | 2011-12-31 | $563,324 | — | — |
| Q3 2011 | 2011-09-30 | $623,318 | −$376,947 | −37.68% |
| Q2 2011 | 2011-06-30 | $795,118 | −$100,533 | −11.22% |
| Q1 2011 | 2011-03-31 | $749,299 | — | — |
| Q3 2010 | 2010-09-30 | $1.0M | — | — |
| Q2 2010 | 2010-06-30 | $895,651 | — | — |
SANUWAVE Health r&d spending trends
Over the last five fiscal years, SANUWAVE Health's r&d spending increased from $1.2M to $1.4M, a change of $107,000. The latest reported quarter, Q2 2026, shows $628,000.
What research and development spending means
Research and development (R&D) spending covers the costs of creating and improving products, services, software, technologies, and processes. Higher R&D spending may support future innovation, but the amount alone does not show whether those investments will generate returns.
SEC-reported R&D expense
TickerStat standardizes research and development expense reported in company SEC filings, including the software-specific US-GAAP R&D concept when it is the filer’s primary R&D expense line. It is historical company-reported spending, not an estimate or forecast. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review SANUWAVE Health source filings ↗